**Table S4. Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA) at baseline and least-squares mean change from baseline at 12 and 52 weeks**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **WPAI-RA** | **Baseline, mean (SD)** | | | **Week 12, LSM ∆ from baseline (95% CI)** | | | **Week 52, LSM ∆ from baseline (95% CI)** | |
| **Question administered to all patients** | **Placebo (N=488)** | **Baricitinib  4 mg QD (N=487)** | **Adalimumab**  **40 mg Q2W (N=330)** | **Placebo (N=488)** | **Baricitinib  4 mg QD (N=487)** | **Adalimumab**  **40 mg Q2W (N=330)** | **Baricitinib  4 mg QD (N=487)** | **Adalimumab**  **40 mg Q2W (N=330)** |
| Percent activity impairment due to RA | 56 (25) | 58 (24) | 58 (26) | -12 (-14, 10) | -24\*\*\*++ (-26, -22) | -19\*\*\* (-22, -17) | -30 (-32, -27) | -28 (-31, -25) |
| **Questions administered to patients who were employed** |  |  |  |  |  |  |  |  |
| Percent employed at time pointa, n (%) | 206 (42.3) | 199 (40.9) | 140 (42.6) | 175 (89.7) | 176 (92) | 127 (93) | 128 (82) | 101 (89) |
| Percent impairment while working due to RA (presenteeism) | 42 (25) | 46 (25) | 44 (25) | -10 (-13, -6) | -18\*\*\* (-22, -15) | -14 (-18, -10) | -24 (-28, -20) | -23 (-27, -19) |
| Percent overall work impairment due to RA (work productivity loss) | 44.5 (26.1) | 48.9 (26.4) | 46.6 (26.4) | -8.4 (-12.4, -4.4) | -17.9\*\*\*+ (-21.7, -14.1) | -11.3 (-15.6, -7.0) | -23.5 (-27.9, -19.1) | -23 (-28.0, -18.0) |
| Percent work time missed due to RA (absenteeism)¶ | 12.4 (26.9) | 13.0 (26.1) | 11.9 (25.8) | 1.3 (-2.2, 4.8) | -3.1\* (-6.4, 0.2) | 0.4 (-3.4, 4.2) | -4.1 (-7.7, -0.5) | -3.9 (-8.0, 0.2) |

Data shown are LSM (95% CI) unless otherwise indicated. Abbreviations: CI=confidence interval; LSM=least squares mean; SD=standard deviation

aFor Weeks 12 and 52, % of patients employed at baseline and continued to be employed at the time point.

\*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.001 versus placebo

+p≤0.05, ++p≤0.01, +++p≤0.001 versus adalimumab